First Patient Dosed in ProstACT Program for Prostate Cancer Therapy

Go back to First Patient Dosed in ProstACT Program for Prostate Cancer Therapy
TRANS-LUX CORPORATION (NASDAQ: TLX) Delayed: 9.14 -0.37 (3.89%)
Previous Close $9.51    52 Week High $2.18 
Open $9.26    52 Week Low $0.30 
Day High $9.26    P/E N/A 
Day Low $9.14    EPS $-3.32 
Volume 50,742